U.S. markets open in 6 hours 51 minutes
  • S&P Futures

    4,335.50
    -68.25 (-1.55%)
     
  • Dow Futures

    33,896.00
    -357.00 (-1.04%)
     
  • Nasdaq Futures

    14,184.75
    -316.25 (-2.18%)
     
  • Russell 2000 Futures

    2,005.20
    -26.50 (-1.30%)
     
  • Crude Oil

    83.71
    +0.40 (+0.48%)
     
  • Gold

    1,842.90
    +1.20 (+0.07%)
     
  • Silver

    23.83
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1315
    -0.0015 (-0.14%)
     
  • 10-Yr Bond

    1.7350
    0.0000 (0.00%)
     
  • Vix

    29.90
    +1.05 (+3.64%)
     
  • GBP/USD

    1.3478
    -0.0013 (-0.09%)
     
  • USD/JPY

    113.7820
    -0.1780 (-0.16%)
     
  • BTC-USD

    36,002.46
    +766.34 (+2.17%)
     
  • CMC Crypto 200

    817.53
    +6.93 (+0.86%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,131.34
    -457.03 (-1.66%)
     

Why Did HCW Biologics Shares More Than Double Today?

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • HCWB
  • Recently listed HCW Biologics Inc (NASDAQ: HCWB) shares almost doubled during premarket Thursday, after FDA signed off Phase 1b trial of its lead candidate in pancreatic cancer.

  • The drug candidate, HCW9218, is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity while simultaneously blocking unwanted immunosuppressive activities.

  • In preclinical studies, HCW9218 enhanced the anti-tumor efficacy of chemotherapy docetaxel and gemcitabine plus nab-paclitaxel against melanoma and pancreatic cancer, respectively, and simultaneously alleviated the off-target, unwanted effects of chemotherapies on normal tissues.

  • In animal models, HCW9218 also augmented anti-tumor activities of therapeutic and checkpoint antibodies.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: HCWB shares are up 101.4% at $5.88 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.